Quarterly report pursuant to Section 13 or 15(d)

Supplemental Disclosure for Statement of Cash Flows (Details)

v3.24.0.1
Supplemental Disclosure for Statement of Cash Flows (Details) - USD ($)
$ in Thousands
6 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Jul. 31, 2023
Supplemental Disclosure for Statement of Cash Flows (Details) [Line Items]      
Interest paid $ 184 $ 106  
Cash flows from operating activities (22,312) (14,891)  
Escrowed proceeds   $ 5,000
Restricted cash collateral deposit 1,000  
Gain on sale of certain assets 729    
Tax on capital 23 9  
Tax on capital paid 467    
Prepaid and Other Assets [Member]      
Supplemental Disclosure for Statement of Cash Flows (Details) [Line Items]      
Escrowed proceeds 5,000    
Enzo Clinical Labs [Member]      
Supplemental Disclosure for Statement of Cash Flows (Details) [Line Items]      
Restricted cash collateral deposit 1,000    
Right of Use Assets and Liabilities [Member]      
Supplemental Disclosure for Statement of Cash Flows (Details) [Line Items]      
Cash flows from operating activities $ 254 $ 2